15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A French Value Set for the EQ-5D-5L

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          The objective of this study was to develop a French value set for the EQ-5D-5L, for academic and clinical research, and for regulatory requirements for price-setting of drugs and medical devices.

          Method

          This study used the standardized valuation protocol developed by EuroQol, using computer-assisted personal interview software. A representative sample of 1048 French residents were interviewed by a market research company, under the supervision of the research team. Health states were valued using composite time trade-off and a discrete choice experiment. Modeling was used to create values for the 3125 possible health states. The composite time trade-off data were modeled using a Tobit model with censored observations at −1 and correcting for heteroscedasticity. A conditional logit model was used for the discrete choice results, and both models were combined using a hybrid model. An adjusted hybrid model was tested to correct for imbalance in the sample on age and sex compared with the general population. A comparison with the 3-level (3L) value set was performed.

          Results

          The adjusted model was preferred to comply with the representativeness of the general population. It provided a value set for which all coefficients were logically consistent. Values ranged from − 0.525 to 1. The distribution of values presented a shift towards higher values versus the 3L value set. Ranking of dimensions changed. Pain and discomfort and mobility were the dimensions with the highest potential for disutility compared with mobility and self-care for the 3L instrument.

          Conclusions

          This study provides a value set based on societal preferences of the French population, using an improved descriptive instrument of health-related quality-of-life health states. It will contribute to improve the quality of cost-effectiveness analysis in the French context and help stimulate disease-specific quality-of-life references for academic-, institutional-, and industry-promoted studies.

          Electronic supplementary material

          The online version of this article (10.1007/s40273-019-00876-4) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.

          To describe the research that has been undertaken by the EuroQol Group to improve current methods for health state valuation, to summarize the results of an extensive international pilot program, and to outline the key elements of the five-level EuroQol five-dimensional (EQ-5D-5L) questionnaire valuation protocol, which is the culmination of that work.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found
            Is Open Access

            Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients.

              The objectives of this study were: 1) to determine whether expanding the number of levels (ie, response categories) on the standard 3 level EQ-5D (EQ-5D-3L) to 5-levels (EQ-5D-5L) would improve the descriptive richness and ability of the measure to discriminate among different levels of health, and 2) to examine the psychometric properties of each EQ-5D version in patients with cancer. U.S.-based cancer patients self-assessed their health using EQ-5D-3L and EQ-5D-5L. These versions were compared in terms of ceiling effects, convergent validity based on correlations with ECOG performance status and FACT-G, discriminative ability using Rasch analysis, and informational richness using Shannon's Evenness Index (J'). A ceiling effect was observed among a greater proportion of respondents to EQ-5D-3L, n=74/424 (17%), compared with EQ-5D-5L, n=47/424 (11%). Within the midlevel of EQ-5D-3L (some problems), substantial partitioning of the sample into the 3 nonextreme levels of the EQ-5D-5L was observed across dimensions. EQ-5D-5L demonstrated a trend towards slightly stronger correlations with ECOG performance status compared with EQ-5D-3L for all dimensions of health, ie, rs (5L/3L): rmobility=0.38/0.31; rself-care=0.35/0.31; rusual activities=0.55/0.47; rpain/discomfort=0.43/0.37; ranxiety/depression=0.23/0.16; rcrude summary score=0.56/0.49. EQ-5D-5L demonstrated a greater relative efficiency and ability to discriminate different levels of health. Informational richness and evenness of EQ-5D-5L was slightly higher (J'5L=0.75) than EQ-5D-3L (J'3L=0.69). Evidence supported the validity of both EQ-5D-3L and EQ-5D-5L in cancer. However, results suggest a 5-level classifier system has less ceiling effect and greater discriminative ability with potentially more power to detect differences between groups compared with EQ-5D-3L.
                Bookmark

                Author and article information

                Contributors
                luizflaro81@gmail.com
                ludwig@euroqol.org
                jramos@axentiva.com
                moppe@axentiva.com
                pouvourville@essec.edu
                Journal
                Pharmacoeconomics
                Pharmacoeconomics
                Pharmacoeconomics
                Springer International Publishing (Cham )
                1170-7690
                1179-2027
                8 January 2020
                8 January 2020
                2020
                : 38
                : 4
                : 413-425
                Affiliations
                [1 ]GRID grid.432649.e, ISNI 0000 0001 0666 5255, Ecole Supérieure de Sciences Economiques et Commerciales (ESSEC Business School), ; 3, Avenue Bernard Hirsch, CS 50105, Cergy Pontoise, France
                [2 ]GRID grid.478988.2, ISNI 0000 0004 5906 3508, Euroqol Research Foundation, ; Marten Meesweg 107, 3068 AV Rotterdam, The Netherlands
                [3 ]Axentiva Solutions, Calle Calvario, 271-1 B, 38340 Tacoronte, Tenerife Spain
                Author information
                http://orcid.org/0000-0002-5941-6823
                Article
                876
                10.1007/s40273-019-00876-4
                7080328
                31912325
                a1431ec0-e514-4ae8-989a-751874ead4a8
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

                History
                Funding
                Funded by: EuroQol
                Award ID: EQ 20170510
                Funded by: AbbVie (FR)
                Award ID: 1768005
                Funded by: Allergan (FR)
                Award ID: P-2018-7046
                Funded by: Amgen (FR)
                Award ID: FR 17 10 507
                Funded by: Biogen (FR)
                Award ID: 1868106
                Funded by: BMS (FR)
                Award ID: 1768053
                Funded by: GSK (FR)
                Award ID: Contract 05/07/2018
                Funded by: Janssen Cilag
                Award ID: 1768065
                Funded by: MSD (FR)
                Award ID: 1768064
                Funded by: Lilly (FR)
                Award ID: Contract 11/24/2017
                Funded by: Novartis (FR)
                Award ID: 1768051
                Funded by: Roche (FR)
                Award ID: Contract 01/08/2018
                Funded by: Sanofi (FR)
                Award ID: 1768122
                Categories
                Original Research Article
                Custom metadata
                © Springer Nature Switzerland AG 2020

                Economics of health & social care
                Economics of health & social care

                Comments

                Comment on this article